Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28114013 | 0.91 | NFKB1 (0.39) | NFKB1MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL163605 | 0.87 | SLC22A12 (0.41) | NFKB1MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL6854167 | 0.87 | NFKB1 (0.47) | NFKB1MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL26617639 | 0.85 | NFKB1 (0.38) | NFKB1MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL8111349 | 0.85 | ALDH1A1 (0.39) | NFKB1MEN1KMT2AALDH1A1TDP1 | |
| Fluoride SCHEMBL31028112 | 0.85 | SLC22A12 (0.40) | NFKB1MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL677594 | 0.85 | NFKB1 (0.42) | NFKB1PIM1PIM3MAOBP4HB | |
| SCHEMBL909840 | 0.85 | MEN1 (0.61) | NFKB1MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL30361071 | 0.85 | CA1 (0.43) | NFKB1MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL29034751 | 0.80 | ACP1 (0.36) | NFKB1MEN1KMT2AALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018255-B2 | Esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them, and their use as inhibitors of the thioredoxin—thioredoxin reductase system | Instytut Chemii Organicznej Polskiej Akademii Nauk (PL) | 2015-04-28 | — | — | US | claimed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | claimed |
| US-12006294-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-06-11 | — | — | US | disclosed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| US-9984878-B2 | Resist under layer film composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20160342088-A1 | RESIST UNDER LAYER FILM COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| CN-103547563-B | Biphenyl derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-03-23 | — | — | CN | disclosed |
| WO-2015008234-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-01-22 | — | — | WO | disclosed |
| CN-103547570-A | Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV | 2014-01-29 | — | — | CN | disclosed |
| CN-103547563-A | Biphenyl derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV | 2014-01-29 | — | — | CN | disclosed |
| EP-1390336-A1 | METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2004-02-25 | — | — | EP | disclosed |
| WO-2003105237-A1 | SYNTHESIS OF PERYLENE-PORPHYRIN BUILDING BLOCKS AND POLYMERS THEREOF FOR THE PRODUCTION OF LIGHT-HARVESTING ARRAYS | NORTH CAROLINA STATE UNIVERSITY (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030075216-A1 | Synthesis of perylene-porphyrin building blocks and polymers thereof for the production of light-harvesting arrays | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-24 | — | — | US | disclosed |
| WO-2002096849-A1 | METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2002-12-05 | — | — | WO | disclosed |
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-6376712-B2 | REDUCTION OF THE CORRESPONDING OXIME COMPOUND | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-04-23 | — | — | US | disclosed |
| US-20020042541-A1 | Process for producing bis( trifluoromethyl)benzaldehyde | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-04-11 | — | — | US | disclosed |
| US-20020013500-A1 | Process for producing trifluoromethylbenzylamines | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-01-31 | — | — | US | disclosed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | NFKB1 2378/4885MEN1 1702/4885KMT2A 3291/4885 |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | OPRL1, INA, OGFR | NFKB1 753/4885MEN1 4058/4885KMT2A 3083/4885 |
| US-20020013500-A1 | Process for producing trifluoromethylbenzylamines | MAOB, CYP2F1, AGL | NFKB1 3338/4885MEN1 2111/4885KMT2A 1182/4885 |
| US-12006294-B2 | Therapeutic compounds | OPRL1, INA, OGFR | NFKB1 753/4885MEN1 4058/4885KMT2A 3083/4885 |
| US-20020042541-A1 | Process for producing bis( trifluoromethyl)benzaldehyde | BRPF1, PFAS, FLI1 | NFKB1 922/4885MEN1 639/4885KMT2A 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.